Xiangrui Fu
Overview
Explore the profile of Xiangrui Fu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
14
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jia Q, Zuo A, Song H, Zhang C, Fu X, Hu K, et al.
Diabetes Obes Metab
. 2024 Dec;
27(3):1276-1286.
PMID: 39691984
Aims: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are known to improve cardiovascular outcomes in individuals with heart failure (HF), type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). However, their efficacy...
2.
Liu Y, Zhang X, Fu X, Li W, Wang Y, Lu W
J Am Med Dir Assoc
. 2024 Nov;
:105334.
PMID: 39521019
Objective: This meta-analysis aimed to qualitatively analyze the different aspects of the successful aging (SA) criteria and quantitatively assess the rate of SA and its different dimensions among people aged...
3.
Jin T, Fu X, Liu M, An F
Diabetol Metab Syndr
. 2023 Apr;
15(1):87.
PMID: 37120554
Background: Finerenone is a third-generation mineralocorticoid receptor antagonists, which has shown good cardiac function improvement in patients with type 2 diabetes in large-scale clinical trials. However, its specific role in...
4.
Liu D, Zhang M, Tian J, Gao M, Liu M, Fu X, et al.
J Hypertens
. 2022 Jul;
40(9):1666-1681.
PMID: 35881419
Background: The migration, proliferation and apoptosis of vascular smooth muscle cells (VSMCs) are critical for plaque stability. WNT-inducible signalling pathway protein-1 (WISP1), a member of the CCN family of extracellular...